|
Post by sportsrancho on Oct 1, 2016 20:02:48 GMT -5
From ST. A MNKD long went to the booth. Barnstormer @rooksleanne @just4sc @kcphaeton it was very cool. The MNKD booth was consistently busy and the spirometer was working overtime Oct 1, 2016 A comment on ST: more than a clever idea, this is proactive targeting to get people to market - UNDERSTAND ONE THING, this is good for a number of reasons and implication that are prerequisite to success- original thinking -diagram process- volume.
|
|
|
Post by gonetotown on Oct 1, 2016 20:13:55 GMT -5
I took a look at her twitter feed. She's welcome to post whatever she wants, but her posts attacking H and defending T are sure to piss off approximately half her potential readers. Don't anyone get me wrong or put words in my mouth. LJ is free to tweet about diabetes and / or politics but IMO she should stick to one or the other per twitter account. Of course, maybe she tweets the politics in an attempt to build an audience. I just think she would have better overall success if she separated her messages. I most definitely agree. I could care less who she attacks or defends, but her efforts come across as just too over the top if not just plain weird.
|
|
|
Post by gonetotown on Oct 1, 2016 20:16:58 GMT -5
Is it avaialable online anywhere? Does she say anything about afrezza?
|
|
|
Post by mnholdem on Oct 1, 2016 20:24:37 GMT -5
If you zoom in on the page buried below the top magazine, you'll read in boldface, "your dose of Afrezza may need to change because of..."
This looks like the last page of a multiple full page ad for Afrezza. The fact that it's placed right in the middle of the article sort of negates the effect of the editor not printing the name of the brand of inhaled insulin, don't you think?
|
|
|
Post by mnkdfann on Oct 1, 2016 21:39:38 GMT -5
This looks like the last page of a multiple full page ad for Afrezza. The fact that it's placed right in the middle of the article sort of negates the effect of the editor not printing the name of the brand of inhaled insulin, don't you think? It might be a multi-page ad, it may not be. You may well be correct. But, really, I don't know see how we can tell from the info we have. AFAIK, the article mentions 'inhaled' once so I think it is not at all clear that a reader will automatically associate the ad with the article. Let's be honest, many people these days are such poor readers they might not even notice / mentally skip over that word. And if the article is really engrossing, one can argue that a reader will skip the ad entirely. Anyway, of course I think the ad is a positive. It's just a matter of how positive. Well, I'll hope for the best.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 1, 2016 22:32:24 GMT -5
Magazine ads are only going to be effective to those that actually like/enjoy/are interested/are passionate about the particular subject/genre the magazine represents. Magazine ads to help market Afrezza is fine, but it needs to be done right or not at all if it is going to cost MannKind money to do so. If Afrezza was the front cover or even the highlight of the magazine issue it would be worth it. In my opinion, in order to actually resonate with a large diabetic audience, we need TV time, and I do not mean just a TV commercial. We need an actual headliner interview involving 2-3 Afrezza success stories, all different and all highlighting various obstacles/life struggles that viewers will be able to relate and connect with. Castagna also needs to be present in it and he does not need to be the center of attention, but only to highlight/recap on certain aspects and questions regarding Afrezza. We need a 60 minutes or an exclusive 30 minute interview on a major network/channel. We also need serious radio coverage—interviews with Afrezza users via the radio, and a MannKind representative on there as well—Castagna. We need Afrezza presentations at medical conferences. That is an easy and effective way to reach providers, and they do not have to just be endos it can be family med, internal med, emergency med, etc. Afrezza doesn't need to be polluted all over TV, etc. to become successful, it just needs a chance to be featured on tv and radio and medical conferences to reach a wide range of people and for many it will probably be the first time hearing of it. Even just MannKind hosting a diabetic concert night, with Stevie Wonder headlining would be better than what they are currently doing. The Alfred Mann Fondation awarded Stevie the Innovation and Inspiration award back in '07. Stevie still does shows in small venues for charities and fundraisers beause I went to one last year. If Mike Lindell, the My Pillow dude, can go from being addicted to crack and gambling to having the most successful infomercial in the world with a company of over 500 employees and generates nearly $100 million in sales, then surely the minds of MannKind can figure it out.
|
|
|
Post by mnholdem on Oct 2, 2016 7:12:28 GMT -5
I think MannKind doesn't have any problem figuring it out, but they're on a "shoestring budget" as one writer penned recently in his article where he states that he thinks MannKind will do a better job of marketing Afrezza than Sanofi did. The DTP marketing is a smart, prudent target because your audience is strictly physicians and patients with diabetes. Granted, talk shows are a low-cost option, but it's not as easy to get on a talk show as many think. The only chance of hitting 60 Minutes would be a story about Alfred Mann's dream, and I doubt that they would even be interested unless there were some scandal involved with the FDA or something. Your statement is interesting, though, that magazine ads are only going to be effective to those who are interested in the subject the particular magazine represents. Readers of Diabetes Health Monitor are exactly the population MannKind should be focusing its efforts on, IMHO. Direct mailings is also effective. Even though costs are higher, DM can result in a higher ROI. In my opinion, MannKind should ship an inhaler and red demonstration cartridge with its DTP literature. Get the Dreamboat into the hands of patients. Let them handle it and you'll capture the patient / physician's interest in a way that a brochure alone cannot. The inhalers are already being handed out at the JDRF/ADA diabetes walk events...let's expand on that idea.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 2, 2016 7:23:38 GMT -5
^^ mailing an inhaler with dummy red catridges is a neat idea.
|
|
|
Post by anthony7 on Oct 2, 2016 8:16:43 GMT -5
Mass marketing will get awareness.
Awareness generates interest.
Interest will result in free samples.
Happy folks generate pressure on insurance companies.
Can you think of any $2 billion drug that failed to budget for mass media advertising? I cannot.
|
|
|
Post by kball on Oct 2, 2016 8:25:05 GMT -5
I think MannKind doesn't have any problem figuring it out, but they're on a "shoestring budget" as one writer penned recently in his article where he states that he thinks MannKind will do a better job of marketing Afrezza than Sanofi did. The DTP marketing is a smart, prudent target because your audience is strictly physicians and patients with diabetes. Granted, talk shows are a low-cost option, but it's not as easy to get on a talk show as many think. The only chance of hitting 60 Minutes would be a story about Alfred Mann's dream, and I doubt that they would even be interested unless there were some scandal involved with the FDA or something. Your statement is interesting, though, that magazine ads are only going to be effective to those who are interested in the subject the particular magazine represents. Readers of Diabetes Health Monitor are exactly the population MannKind should be focusing its efforts on, IMHO. Direct mailings is also effective. Even though costs are higher, DM can result in a higher ROI. In my opinion, MannKind should ship an inhaler and red demonstration cartridge with its DTP literature. Get the Dreamboat into the hands of patients. Let them handle it and you'll capture the patient / physician's interest in a way that a brochure alone cannot. The inhalers are already being handed out at the JDRF/ADA diabetes walk events...let's expand on that idea. Time for the outsulin character to evolve a bit.
Mannkind has been bullied by seemingly everyone...and that outsulin doodle with only one eyebrow reminds me too much off that drunken fraternity prank
|
|
|
Post by victoria on Oct 2, 2016 8:32:45 GMT -5
^^ mailing an inhaler with dummy red catridges is a neat idea. Mike Casagna if you are reading this thread: if attaching a dummy cartridge and inhaler to a mag as part of dtc (like they used to give away floppy disks on computer mags years ago) can be done legally as part of an afrezza ad, I think this is a brilliant idea. Pay for a cover feature on front of a diabetes mag, attach the inhaler. It costs a bit, but get the device in the hands of diabetic people and parents and it will be a good thing. Better still attach a dvd with instructional videos on it as well which you already have. That's probably only a few cents per copy. I hope someone here passes the attached inhaler idea to him. I wonder if it's legal to send dummy inhalers direct to docs? Zero commercial value, not an actual device so not fall foul of rules re gifts to docs?
|
|
|
Post by victoria on Oct 2, 2016 8:39:47 GMT -5
I think MannKind doesn't have any problem figuring it out, but they're on a "shoestring budget" as one writer penned recently in his article where he states that he thinks MannKind will do a better job of marketing Afrezza than Sanofi did. The DTP marketing is a smart, prudent target because your audience is strictly physicians and patients with diabetes. Granted, talk shows are a low-cost option, but it's not as easy to get on a talk show as many think. The only chance of hitting 60 Minutes would be a story about Alfred Mann's dream, and I doubt that they would even be interested unless there were some scandal involved with the FDA or something. Your statement is interesting, though, that magazine ads are only going to be effective to those who are interested in the subject the particular magazine represents. Readers of Diabetes Health Monitor are exactly the population MannKind should be focusing its efforts on, IMHO. Direct mailings is also effective. Even though costs are higher, DM can result in a higher ROI. In my opinion, MannKind should ship an inhaler and red demonstration cartridge with its DTP literature. Get the Dreamboat into the hands of patients. Let them handle it and you'll capture the patient / physician's interest in a way that a brochure alone cannot. The inhalers are already being handed out at the JDRF/ADA diabetes walk events...let's expand on that idea. Time for the outsulin character to evolve a bit.
Mannkind has been bullied by seemingly everyone...and that outsulin doodle with only one eyebrow reminds me too much off that drunken fraternity prankI think Outsulin actually practises martial arts and will kick insulin's ass at some stage. That lost eyebrow was likely lost in the gym tackling a gang of twelve syringes armed with sharp needles. Picture exhausted syringes lying panting on the ground with bent needles. Or a roadrunner style saga of outsulin (meep meep!) outdoing insulin every time. Animators, get on it!
|
|
|
Post by mnholdem on Oct 2, 2016 9:29:07 GMT -5
I always thought that Brits used term "arse" but when in Rome, eh? BTW, the eyebrows are both there on the OUTsulin character. Zoom in and you'll see it with a darker coloration in the lower dark stripe on the sweat band.
|
|
|
Post by victoria on Oct 2, 2016 9:41:53 GMT -5
I always thought that Brits used term "arse" but when in Rome, eh? BTW, the eyebrows are both there on the OUTsulin character. Zoom in and you'll see it with a darker coloration in the lower dark stripe on the sweat band. May be just me but I think we over here nowadays tend to use 'ass' (adopted from the US version) as a way of being more polite (and we would pronounce it 'ass'). 'arse' (pronounced with the 'r') is the sort of word you might not use in front of your granny but 'ass' you might feel ok with. Odd I know...
|
|
|
Post by kball on Oct 2, 2016 10:55:08 GMT -5
I always thought that Brits used term "arse" but when in Rome, eh? BTW, the eyebrows are both there on the OUTsulin character. Zoom in and you'll see it with a darker coloration in the lower dark stripe on the sweat band. Good eye, thanks. As mine fail. Still feel design needs finessing just a bit. Maybe i'm the only one who missed it?
|
|